Key Takeaways
- UnitedHealth stock advanced 1.5% during Monday’s session, reaching an intraday peak of $283.30 and settling at $281.46.
- CMS released its final 2027 Medicare Advantage payment rate at 2.48%, dramatically exceeding the preliminary 0.09% figure from January.
- The revised rate will result in approximately $13 billion in incremental federal payments to health insurers throughout the coming year.
- Ahead of first-quarter earnings scheduled for April 21, Raymond James elevated UNH to “outperform” from “market perform” with a $330 target price.
- In premarket trading following the Medicare announcement, Humana surged 11% while UNH and CVS Health each climbed over 6%.
Shares of UNH began Monday’s trading session at $277.26, climbing to $283.30 during the day before finishing at $281.46 — marking a 1.5% increase.
UnitedHealth Group Incorporated, UNH
The healthcare giant’s shares have declined approximately 22% during the previous six-month period and currently trade beneath both the 50-day moving average of $283.03 and the 200-day moving average of $319.62. Wall Street analysts maintain a consensus price objective of $363.38.
Following the market close on Monday, the Centers for Medicare and Medicaid Services (CMS) unveiled its final payment rate structure for 2027 Medicare Advantage programs. The determination established a 2.48% average rate increase — representing a substantial improvement over January’s preliminary 0.09% figure that had generated significant concern throughout the healthcare insurance industry.
When that preliminary January estimate was disclosed, it triggered selloffs in UNH and Humana shares. Market participants had been anticipating potential revisions in the final determination.
The enhanced payment structure equates to roughly $13 billion in supplementary insurer compensation for the upcoming year. Following the announcement, UNH and CVS Health, which owns Aetna, experienced premarket gains exceeding 6%. Humana shares jumped 11%.
Why Medicare Advantage Matters for Insurers
Medicare Advantage represents the private-sector option to conventional Medicare, currently serving approximately 35 million enrollees this year based on data from health policy organization KFF. The program has experienced consistent enrollment expansion and has now surpassed traditional Medicare in participant numbers.
For major health insurers like UnitedHealth, this segment represents a critical revenue component. The prospect of a near-zero rate adjustment — particularly when medical expense inflation runs between 7% and 9% annually — would have functioned as an effective payment reduction, according to analysis from the Better Medicare Alliance.
Mizuho Securities analyst Jared Holz characterized the 2.48% final determination as “certainly better than the government’s initial rate decision,” noting that it establishes conditions for potential margin improvement in the coming year should companies maintain their benefit optimization and cost management strategies.
TD Cowen analyst Ryan Langston had projected a more conservative adjustment in the 1% to 1.5% range, meaning the actual figure surpassed certain market forecasts.
Cross-party political dynamics had complicated the rate outlook. Lawmakers from both major parties have expressed concerns regarding insurers receiving elevated payments through diagnostic coding practices — commonly referred to as risk adjustment. The previous administration initiated stricter oversight of these mechanisms, and the January preliminary proposal indicated ongoing regulatory attention.
First Quarter Results Due April 21
On April 1, Raymond James elevated its rating on UNH from “market perform” to “outperform,” establishing a $330 price objective. The investment firm pointed to opportunities for leadership to demonstrate operational stabilization heading into the earnings release.
Barclays maintains an “overweight” stance with a $327 target. Mizuho and Leerink Partners similarly assign “outperform” ratings, with price objectives of $350 and $345, respectively.
Among 28 analysts tracking the company, 18 recommend Buy, seven advise Hold, and two suggest Sell. MarketBeat’s aggregated consensus registers as Moderate Buy.
First-quarter financial results are scheduled for release on April 21. During the fourth quarter, UNH delivered $2.11 in earnings per share, exceeding the analyst consensus of $2.09. Total revenue reached $113.73 billion, representing 12.3% year-over-year growth. Management has provided fiscal 2026 EPS guidance of $17.75.
UNH distributes a quarterly dividend of $2.21 per share, translating to a 3.1% annualized yield at current trading levels.
Institutional investors control 87.86% of outstanding shares, with recent stake increases from Norges Bank, Berkshire Hathaway, and T. Rowe Price.
